Proterguride, a highly potent dopamine receptor agonist promising for transdermal administration in Parkinson's disease: Interactions with α1-, 5-HT2- and H1-receptors-Reference-Cited by-同舟云学术

Proterguride, a highly potent dopamine receptor agonist promising for transdermal administration in Parkinson's disease: Interactions with α1-, 5-HT2- and H1-receptors

Published:2006-04 Issue:20 Volume:78 Page:2358-2364
ISSN:0024-3205
Container-title:Life Sciences
language:en
Short-container-title:Life Sciences

Author:

Schurad B.,Horowski R.,Jähnichen S.,Görnemann T.,Tack J.,Pertz H.H.

Publisher

Elsevier BV

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference35 articles.

1. Partial dopamine agonist therapy of levodopa-induced dyskinesias;Baronti;Neurology,1992

2. 5-Hydroxytryptamine2A receptors regulate sympathetic nerves constricting the cutaneous vascular bed in rabbits and rats;Blessing;Neuroscience,2003

3. Postjunctional alpha-1 and alpha-2 adrenoceptors in human skin arteries. An in vitro study;Borbujo;Journal of Pharmacology and Experimental Therapeutics,1989

4. Rationale for continuous dopaminomimetic therapy of Parkinson's disease;Chase;Neurology,1989

5. Characterization of the α1-adrenoceptor subtype mediating contraction of guinea pig spleen;Eltze;European Journal of Pharmacology,1994

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dopamine, a co-regulatory component, bridges the central nervous system and the immune system;Biomedicine & Pharmacotherapy;2022-01

2. Recent trends in the transdermal delivery of therapeutic agents used for the management of neurodegenerative diseases;Journal of Drug Targeting;2016-11-08

3. Inflammation;Molecular Basis of Health and Disease;2011

4. Characterization of the Molecular Fragment That Is Responsible for Agonism of Pergolide at Serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A Receptors;Journal of Pharmacology and Experimental Therapeutics;2007-12-20

5. Experimental Models and New, Emerging Therapies for Parkinson Disease;Principles and Practice of Movement Disorders;2007